Mark Ogle, MD
Psychiatry · Indianapolis, INNPI 1801842422
Payments from drug & device makers
Across 327 payments — averaging $15.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Johnson & Johnson$439
- Otsuka America Pharmaceutical, Inc.$432
- Lundbeck LLC$390
- Neurocrine Biosciences, Inc.$351
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$289
- plus $2K from 23 others
What the payments were for
- Food & beverage$5,12599%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 116 | $1,568 |
| Johnson & Johnson | 22 | $439 |
| Otsuka America Pharmaceutical, Inc. | 20 | $432 |
| Lundbeck LLC | 23 | $390 |
| Neurocrine Biosciences, Inc. | 21 | $351 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 16 | $289 |
| Vanda Pharmaceuticals Inc. | 16 | $265 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $198 |
| Teva Pharmaceuticals USA, Inc. | 13 | $177 |
| Sunovion Pharmaceuticals Inc. | 9 | $128 |
| Eisai Inc. | 7 | $113 |
| Axsome Therapeutics, Inc. | 5 | $87 |
| Merck | 5 | $86 |
| Corium, LLC | 5 | $84 |
| Bausch Health US, LLC | 6 | $82 |
| Ironshore Pharmaceuticals Inc. | 4 | $67 |
| Avanir Pharmaceuticals, Inc. | 3 | $60 |
| Alkermes, Inc. | 4 | $59 |
| Neos Therapeutics, LP | 3 | $49 |
| Jazz Pharmaceuticals Inc. | 3 | $48 |
| E.r. Squibb & Sons, L.L.C. | 2 | $34 |
| Supernus Pharmaceuticals, Inc. | 2 | $32 |
| OWP Pharmaceuticals, Inc. | 2 | $31 |
| Adlon Therapeutics L.p. | 2 | $28 |
| Almatica Pharma LLC | 1 | $19 |
| Sun Pharmaceutical Industries Inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Acadia Pharmaceuticals Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,172 in reported general payments places this provider in the 85th percentile of 514 psychiatry providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 44 | $368,270 |
| CaplytaLumateperone Tosylate | 71 | $118,916 |
| TrintellixVortioxetine Hydrobromide | 142 | $103,544 |
| VraylarCariprazine Hcl | 50 | $89,605 |
| Austedo XrDeutetrabenazine | 11 | $79,907 |
| RexultiBrexpiprazole | 31 | $37,068 |
| Olanzapine | 392 | $21,927 |
| Aripiprazole | 319 | $20,245 |
| Bupropion XlBupropion Hcl | 584 | $16,425 |
| Paroxetine Hcl | 140 | $12,411 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 127 | $11,102 |
| Duloxetine Hcl | 328 | $10,988 |
| Lurasidone Hcl | 44 | $10,037 |
| Divalproex Sodium ErDivalproex Sodium | 88 | $9,874 |
| Quetiapine Fumarate | 311 | $8,951 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $351 | $368,27044 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $289 | $118,91671 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $198 | $111,199160 claims |
| AbbVieVraylar | $1,568 | $89,60550 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $177 | $79,90711 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $432 | $37,06831 claims |
| MerckBelsomra | $86 | $8,60319 claims |
| Eisai Inc.Dayvigo | $113 | $3,39211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 514 psychiatry providers in Indiana.
Other psychiatry in Indianapolis
- Anantha ShekharIndianapolis$433K
- Leslie HulvershornIndianapolis$159K
- Charles BeasleyIndianapolis$129K
- Alan BreierIndianapolis$114K
- John NurnbergerIndianapolis$104K
- Susan ConroyIndianapolis$73K
- Dmitry ArbuckIndianapolis$40K
- Michael FrancisIndianapolis$26K
- Albert AllenIndianapolis$24K
- Jerad DaltonIndianapolis$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.